Clinical Trial Update: Impact of Liraglutide 3.0 on Body Fat Distribution [Phase 4]

View source ↗

Summary

Phase 4 trial assessing the impact of liraglutide 3.0 on body fat distribution; results published after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Diseases
• Obesity
• Visceral Adiposity

Drugs mentioned

• liraglutide 3.0 (liraglutide)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Obesity, Visceral, Cardiovascular Diseases | Phase 4 | Status: COMPLETED | Results posted: 2021-11-19